Blueshift Asset Management
DMRA

Blueshift Asset Management’s Damora Therapeutics DMRA Stock Holding History

Blueshift Asset Management’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,010
Closed -$128K – 1108
2021
Q2 		$128K Buy
+1,010
New +$138K 0.01% 865

Other funds holding DMRA

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Novo Holdings A/S
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 107.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Cormorant Asset Management
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Bridgeway Capital Management
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Laurion Capital Management
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Blueshift Asset Management's DMRA Position: Q3 2021 in Review

Blueshift Asset Management sold out of Damora Therapeutics (DMRA) in Q3 2021, closing a stake of 1,010 shares — an estimated $128K sold.

Blueshift Asset Management first reported a position in DMRA in Q2 2021 and held it in 1 quarter. The position peaked at $128K in Q2 2021. 25 funds tracked by Wall St. Rank hold DMRA as of Q3 2021.

  • Blueshift Asset Management reported no remaining Damora Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Blueshift Asset Management sold 1,010 Damora Therapeutics shares in Q3 2021, an estimated $128K.
  • Blueshift Asset Management first reported a position in Damora Therapeutics in Q2 2021 and held it in 1 quarter.
  • Blueshift Asset Management's Damora Therapeutics position peaked at $128K in Q2 2021.
  • 25 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2021.

Based on Blueshift Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.